Strides Pharma Science (NSE:STAR) Total Current Assets: ₹36,133 Mil (As of Mar. 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
68 GF Score
Price ₹1,092.90
GF Value ₹775.20
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Total Current Assets?

Strides Pharma Science NSE:STAR -0.95% 68 Total Current Assets is ₹36,133 Mil as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹775.20 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Strides Pharma Science's total current assets for the quarter that ended in Mar. 2026 was ₹36,133 Mil.


Strides Pharma Science  (NSE:STAR) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Strides Pharma Science's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4103.51-37778.95+0.75 * 12889.64+0.5 * 16347.94
=-15,834

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strides Pharma Science Total Current Assets Related Terms


Strides Pharma Science Total Current Assets Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Total Current Assets Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33,644.09 32,459.39 29,724.91 31,016.82 36,133.39

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31,016.82 0.00 33,131.81 0.00 36,133.39
NSE:STAR
68GF Score
Strides Pharma Science Ltd NSE:STAR
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Strides Pharma Science's Total Current Assets for the fiscal year that ended in Mar. 2026 is calculated as

Strides Pharma Science's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of ₹36,133 Mil mean?
Strides Pharma Science (NSE:STAR) has a Total Current Assets of ₹36,133 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Strides Pharma Science and its competitors.
Is Strides Pharma Science's Total Current Assets too high?
Strides Pharma Science's current Total Current Assets is ₹36,133 Mil. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Total Current Assets compare to ZTS and UTHR?
Strides Pharma Science's Total Current Assets of ₹36,133 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Strides Pharma Science and its competitors. Strides Pharma Science's current Total Current Assets is ₹36,133 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹775.20, compared to a current price of ₹1,092.90 — trading 41% above its estimated fair value. The current Total Current Assets is ₹36,133 Mil. Strides Pharma Science's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Total Current Assets is ₹36,133 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,092.90 is trading 41% above its estimated GF Value™ of ₹775.20. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Total Current Assets: ₹36,133 Mil
  • GF Value™: ₹775.20 vs. price of ₹1,092.90 (41% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score

Get the complete analysis for NSE:STAR

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,092.90
Price
₹775.20
GF Value